Coronary disease Trials in Munich, Germany
Conditions / Coronary disease / Munich, Germany
Research into Coronary disease spans multiple therapeutic approaches and trial phases.
16 total trials for this combination
Showing top 10 of 16 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00133237 | Drug-eluting-stents for Unprotected Left Main Stem Disease (ISAR-LEFT-MAIN) | COMPLETED | PHASE4 |
| NCT00598637 | Drug-eluting Stents to Treat Unprotected Coronary Left Main Disease | COMPLETED | PHASE4 |
| NCT00148356 | Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries | COMPLETED | PHASE2/PHASE3 |
| NCT00140465 | 75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2) | COMPLETED | PHASE4 |
| NCT00133003 | Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2) | COMPLETED | PHASE4 |
| NCT00389220 | Limus Eluted From A Durable Versus ERodable Stent Coating | COMPLETED | NA |
| NCT00262054 | Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3) | COMPLETED | PHASE4 |
| NCT00152308 | Non-Polymer-Based, Rapamycin-Eluting Stents to Prevent Restenosis | TERMINATED | PHASE4 |
| NCT00326976 | Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury | COMPLETED | PHASE2 |
| NCT00373451 | Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome | COMPLETED | PHASE4 |